載入...
Monalizumab: inhibiting the novel immune checkpoint NKG2A
The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhi...
Na minha lista:
| 發表在: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6798508/ https://ncbi.nlm.nih.gov/pubmed/31623687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0761-3 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|